Xây dựng mối quan hệ giữa nhà cung cấp dịch vụ chăm sóc sức khỏe và bệnh nhân: Một nghiên cứu định tính về trải nghiệm của những người nhận điều trị chất chủ vận opioid tiêm
Tóm tắt
Điều trị chất chủ vận opioid tiêm (iOAT) được thiết kế như một phương pháp thực tiễn và đầy tính nhân văn cho những người không được hưởng lợi từ điều trị hỗ trợ bằng thuốc opioid đường uống (ví dụ, methadone). Trong khi một khối lượng lớn bằng chứng từ các thử nghiệm lâm sàng đã chứng minh tính an toàn và hiệu quả của iOAT, thì ít thông tin hơn về các khía cạnh tập trung vào bệnh nhân của phương pháp điều trị này và vai trò của chúng trong các mục tiêu và kết quả điều trị được tự báo cáo. Mục tiêu của nghiên cứu này là khám phá trải nghiệm của những người tham gia trong iOAT liên quan rộng rãi đến các lĩnh vực chăm sóc tập trung vào bệnh nhân. Một mục tiêu phụ là khám phá cách những trải nghiệm này ảnh hưởng đến kết quả điều trị tự báo cáo của các tham gia viên.
Một phương pháp định tính và cách tiếp cận lý thuyết xây dựng được sử dụng để hướng dẫn việc lấy mẫu, thu thập và phân tích dữ liệu. Tổng cộng có 30 cuộc phỏng vấn sâu được thực hiện với những người nhận iOAT tại phòng khám đầu tiên ở Bắc Mỹ. Các bản ghi âm của mỗi cuộc phỏng vấn bán cấu trúc đã được phiên âm và đọc nhiều lần. Chiến lược so sánh liên tục được sử dụng thông qua các giai đoạn lặp đi lặp lại của việc mã hóa theo dòng, mã hóa tập trung và mã hóa lý thuyết cho đến khi đạt được độ bão hòa lý thuyết.
Khái niệm cốt lõi gợi ý rằng các mối quan hệ trị liệu là điều cơ bản cho trải nghiệm chăm sóc tập trung vào bệnh nhân trong iOAT. Khi các mối quan hệ được tôn trọng và thấu hiểu, các tham gia viên nhận được sự chăm sóc cá nhân hóa và toàn diện trong iOAT. Những phát hiện này cung cấp một ví dụ giá trị về cách các mối quan hệ trị liệu có thể được củng cố trong các cài đặt điều trị sử dụng chất khác, đặc biệt là khi đáp ứng nhu cầu điều trị đa dạng của khách hàng.
Từ khóa
Tài liệu tham khảo
United Nations publications. World Drug Report 2019. https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_2_DRUG_DEMAND.pdf:: United Nations; 2019. Accessed 23 Dec 2019.
Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths--United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–82.
Schottenfeld RS, O’Malley SS. Meeting the growing need for heroin addiction treatment. JAMA Psychiatry. 2016;73(5):437–8.
Nordt C, Vogel M, Dey M, Moldovanyi A, Beck T, Berthel T, et al. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction. 2019;114(1):103–11.
European Monitoring Center for Drugs and Drug Addiction. New heroin-assisted treatment. Luxembourg: Publications Office of the European Union; 2012.
Oviedo-Joekes E, Palis H, Guh D, Marchand K, Brissette S, Harrison S, et al. Treatment with injectable hydromorphone: comparing retention in double blind and open label treatment periods. J Subst Abus Treat. 2019;101:50–4.
Baker R. Health Canada approves injectable hydromorphone to treat opioid addiction. CBC News. 2019;16:2019.
Bell J, Belackova V, Lintzeris N. Supervised injectable opioid treatment for the Management of Opioid Dependence. Drugs. 2018;78(13):1339–52.
Perneger TV, Giner F, del Rio M, Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ. 1998;317(7150):13–8.
van den Brink W, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003;327(7410):310.
March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abus Treat. 2006;31(2):203–11.
Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2007;191:55–62.
Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet. 2010;375(9729):1885–95.
Demaret I, Quertemont E, Litran G, Magoga C, Deblire C, Dubois N, et al. Efficacy of heroin-assisted treatment in Belgium: A randomised controlled trial. Eur Addict Res. 2015;21(4):179–87.
Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: A randomized clinical trial. JAMA Psychiatry. 2016;73(5):447–55.
Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777–86.
Romo N, Poo M, Ballesta R. From illegal poison to legal medicine: a qualitative research in a heroin-prescription trial in Spain. Drug Alcohol Rev. 2009;28(2):186–95.
Oviedo-Joekes E, Marchand K, Lock K, Chettiar J, Marsh DC, Brissette S, et al. A chance to stop and breathe: participants’ experiences in the north American opiate medication initiative clinical trial. Addict Sci Clin Pract. 2014;9:21–31.
Blanken P, van den Brink W, Hendriks VM, Huijsman IA, Klous MG, Rook EJ, et al. Heroin-assisted treatment in the Netherlands: history, findings, and international context. Eur Neuropsychopharmacol. 2010;20(Suppl 2):S105–58.
Jozaghi E. “SALOME gave my dignity back”: the role of randomized heroin trials in transforming lives in the downtown eastside of Vancouver, Canada. Int J Qual Stud Health Well-being. 2014;9:23698.
Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med. 2000;51(7):1087–110.
McMillan SS, Kendall E, Sav A, King MA, Whitty JA, Kelly F, et al. Patient-centered approaches to health care: a systematic review of randomized controlled trials. Med Care Res Rev. 2013;70(6):567–96.
Scholl I, Zill JM, Harter M, Dirmaier J. An integrative model of patient-centeredness - a systematic review and concept analysis. PLoS One. 2014;9(9):e107828.
Santana MJ, Manalili K, Jolley RJ, Zelinsky S, Quan H, Lu M. How to practice person-centred care: A conceptual framework. Health Expect. 2018;21(2):429–40.
Bradley KA, Kivlahan DR. Bringing patient-centered care to patients with alcohol use disorders. Chicago: American Medical Association; 2014. p. 1861–2.
Marchand K, Oviedo-Joekes E. Prioritizing the patient in patient-centered addictions treatment. Addiction. 2017;112(3):466–7.
Park SE, Grogan CM, Mosley JE, Humphreys K, Pollack HA, Friedmann PD. Correlates of Patient-Centered Care Practices at U.S. Substance Use Disorder Clinics. Psychiatr Serv. 2020;71(1):35–42.
Marchand K, Beaumont S, Westfall J, MacDonald S, Harrison S, Marsh DC, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst Abuse Treat Prev Policy. 2019;14(1):37.
Hinsley K, Kelly PJ, Davis E. Experiences of patient-centred care in alcohol and other drug treatment settings: A qualitative study to inform design of a patient-reported experience measure. Drug Alcohol Rev. 2019;38(6):664–73.
Marchand K, Beaumont S, Westfall J, MacDonald S, Harrison S, Marsh DC, et al. Additional File 6, from “Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review”. Subst Abuse Treat Prev Policy. 2019;14(1):37.
Charmaz K. Constructing grounded theory: A practical guide through qualitative analysis. London: SAGE Publications Ltd; 2006.
Charmaz K. Constructing grounded theory. London: SAGE Publications Ltd; 2014.
Oviedo-Joekes EM, Marchand K, Guh D, MacDonald S, Lock K, Brissette S, Anis AH, Krausz M, Schechter MT. History of treatment access and drug use among participants in a trial testing injectable opioids under supervision for long-term heroin injectors. J Addict Med Ther. 2015;3(1):1015.
Fairbairn N, Ross J, Trew M, Meador K, Turnbull J, MacDonald S, et al. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. CMAJ. 2019;191(38):E1049–E56.
Anstice S, Strike CJ, Brands B. Supervised methadone consumption: client issues and stigma. Subst Use Misuse. 2009;44(6):794–808.
Rance J, Treloar C, Ethos Study Group. ‘Not just methadone Tracy’: transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings. Addiction (Abingdon, England). 2014;109(3):452–9.
Woo J, Bhalerao A, Bawor M, Bhatt M, Dennis B, Mouravska N, et al. “Don’t judge a book its cover”: A qualitative study of methadone Patients’ experiences of stigma. Subst Abuse. 2017;11:1178221816685087.
Harris J, McElrath K. Methadone as social control: institutionalized stigma and the prospect of recovery. Qual Health Res. 2012;22:810–24 United States.
Bourgois P. Disciplining addictions: the bio-politics of methadone and heroin in the United States. Cult Med Psychiatry. 2000;24(2):165–95.
Crawford S. Shouting through bullet-proof glass: some reflections on pharmacotherapy provision in one Australian clinic. Int J Drug Policy. 2013;24(6):e14–7.
Smith CB. A Users’ Guide to ‘Juice Bars’ and ‘Liquid Handcuffs’: Fluid Negotiations of Subjectivity, Space and the Substance of Methadone Treatment. Space Cult. 2011;14(3):291–309.
Radcliffe P, Stevens A. Are drug treatment services only for ‘thieving junkie scumbags’? Drug users and the management of stigmatised identities. Soc Sci Med. 2008;67(7):1065–73.
Fraser S. The chronotope of the queue: methadone maintenance treatment and the production of time, space and subjects. Int J Drug Policy. 2006;17(3):192–202.
Fraser S, Valentine K. Substance and substitution. Methadone subjects in Liberal societies. New York: Palgrave Macmillan; 2008.
Lilly AQTRGVSR. Sociality in methadone treatment: understanding methadone treatment and service delivery as a social process. Drugs. 2000;7(2):163–78.
Deering DE, Sheridan J, Sellman JD, Adamson SJ, Pooley S, Robertson R, et al. Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness. Addict Behav. 2011;36(6):636–42.
Deering D, Horn J, Frampton CMA. Clients’ perceptions of opioid substitution treatment: an input to improving the quality of treatment. Int J Ment Health Nurs. 2012;21(4):330–9.
Woolhouse S, Brown JB, Thind A. ‘Meeting people where They’re At’: experiences of family physicians engaging women who use illicit drugs. Ann Fam Med. 2011;9(3):244–9.
McCallum SL, Mikocka-Walus AA, Gaughwin MD, Andrews JM, Turnbull DA. I’m a sick person, not a bad person’: patient experiences of treatments for alcohol use disorders. Health Expect. 2016;19(4):828–41.
Banazadeh N, Kheradmand A, Abedi H. Opiate dependents’ experiences of the therapeutic relationship in methadone centers; a qualitative study. Addict Health. 2009;1(1):12–8.
Ness O, Kvello O, Borg M, Semb R, Davidson L. “Sorting things out together”: Young adults’ experiences of collaborative practices in mental health and substance use care. Am J Psychiatric Rehabil. 2017;20(2):126.
Rance J, Treloar C. “we are people too”: consumer participation and the potential transformation of therapeutic relations within drug treatment. Int J Drug Policy. 2015;26(1):30–6.
McCall J, Phillips JC, Estafan A, Caine V. Exploring the experiences of staff working at an opiate assisted treatment clinic: an interpretive descriptive study. Appl Nurs Res. 2019;45:45–51.
Reyre A, Jeannin R, Largueche M, Moro MR, Baubet T, Taieb O. Overcoming professionals’ challenging experiences to promote a trustful therapeutic alliance in addiction treatment: A qualitative study. Drug Alcohol Depend. 2017;174:30–8.
Goodhew M, Stein-Parbury J, Dawson A. Consumer participation in drug treatment: a systematic review. Drugs Alcohol Today. 2019;19(2):97–112.
Schwartz RP, Kelly SM, Mitchell SG, Gryczynski J, O'Grady KE, Gandhi D, et al. Patient-centered methadone treatment: a randomized clinical trial. Addiction. 2017;112(3):454–64.
Fox AD, Masyukova M, Cunningham C. Optimizing psychosocial support during office-based buprenorphine treatment in primary care: Patients’ experiences and preferences. Subst Abus. 2016;37(1):70–5.
Ferri M, Davoli M, Perucci AC. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 2012;12:CD003410.
Carlsen SL, Gaulen Z, Alpers SE, Fjaereide M. Beyond medication: life situation of older patients in opioid maintenance treatment. Addict Res Theory. 2019;27(4):305–13.
Neale J, Tompkins C, Wheeler C, Finch E, Marsden J, Mitcheson L, et al. “You’re all going to hate the word ‘recovery’ by the end of this”: service users’ views of measuring addiction recovery. Drugs. 2015;22(1):26–34.
Strada L, Franke GH, Schulte B, Reimer J, Verthein U. Development of OSTQOL: A Measure of Quality of Life for Patients in Opioid Substitution Treatment. Eur Addict Res. 2017;23:1421–9891 (Electronic)):238–48.
Neale J, Vitoratou S, Finch E, Lennon P, Mitcheson L, Panebianco D, et al. Development and validation of ‘Sure’: A patient reported outcome measure (PROM) for recovery from drug and alcohol dependence. Drug Alcohol Depend. 2016;165:159–67.
Alves P, Sales C, Ashworth M. Does outcome measurement of treatment for substance use disorder reflect the personal concerns of patients? A scoping review of measures recommended in Europe. Drug Alcohol Depend. 2017;179:299–308.
Alves PCG, Sales CMD, Ashworth M. Personalising the evaluation of substance misuse treatment: A new approach to outcome measurement. Int J Drug Policy. 2015;26(4):333–5.
Thurgood S, Crosby H, Raistrick D, Tober G. Service user, family and friends’ views on the meaning of a ‘good outcome’ of treatment for an addiction problem. Drugs. 2014;21(4):324–32.